2nd Quarter 2022 Results

2nd Quarter 2022 Sales
Worldwide Increased 8.1%

Diluted Earnings Per Share Decreased (23.4)%
Adjusted Diluted Earnings Per Share* Increased 4.4%

$24.0B 3.0%

Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges. I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.

$3.8 Billion
Consumer Health worldwide reported sales decreased (1.3)%, but increased 2.3% operationally. Primary operational drivers:

- Imodium
- Neutrogena
- Stayfree
- Lubriderm
- SUDAFED

$13.3 Billion
Pharmaceutical worldwide reported sales increased 6.7% or 12.3% operationally. Primary operational drivers:

- Stelara
- Darzalex
- Tremfya
- Xarelto
- INVEGA SUSTENNA

$6.9 Billion
MedTech worldwide reported sales decreased (1.0)%, but increased 3.4% operationally. Primary operational drivers:

- Contact Lens
- Electrophysiology
- Surgical Vision
- Wound Closure
- Embolieters

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.


*Non-GAAP financial measures: non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Non-GAAP measures exclude the impact of translational currency.

Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational change.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. These statements are not based on facts but rather on our current expectations. Forward-looking statements are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statement, refer to the “Risk Factors” section of any forward-looking statements, or to the “Notes to Investors” in our Annual Reports on Form 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.